CYR61 controls p53 and NF-kappa B expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kwang-Beom | - |
dc.contributor.author | Byun, Hyun-Jung | - |
dc.contributor.author | Park, Sung Ho | - |
dc.contributor.author | Park, Chan-Yong | - |
dc.contributor.author | Lee, Seung-Hoon | - |
dc.contributor.author | Rho, Seung Bae | - |
dc.date.available | 2020-02-29T06:45:47Z | - |
dc.date.created | 2020-02-05 | - |
dc.date.issued | 2012-02-01 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16582 | - |
dc.description.abstract | CYR61 over-expression promotes cell proliferation by inhibiting carboplatin-induced apoptosis, decreasing Bax expression, and increasing Bcl-xL, Mcl-1, and Bcl-2. At the same time, down-regulating p53 expression, while up-regulated NF-kappa B expression. Additionally, p21 and p53 promoter activities were reduced, while NF-kappa B and Bcl-2 activities increased. In parallel, CYR61-expressing cells, during carboplatin-induced apoptosis, resulted in an increase of Akt phosphorylation, while rapamycin-treated cells were not affected. Carboplatin effectively inhibited the activation of mTOR signaling cascade, which includes mTOR, 4E-BP1, p70S6K, HIF-1 alpha, and VEGF. These results provide evidence that CYR61 promotes cell proliferation and inhibits apoptosis. (C) 2011 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.relation.isPartOf | CANCER LETTERS | - |
dc.subject | IMMEDIATE-EARLY GENE | - |
dc.subject | CCN FAMILY | - |
dc.subject | BREAST-CANCER | - |
dc.subject | ENDOMETRIAL CANCER | - |
dc.subject | TUMOR-SUPPRESSOR | - |
dc.subject | APOPTOSIS | - |
dc.subject | INHIBITION | - |
dc.subject | GROWTH | - |
dc.subject | BCL-2 | - |
dc.subject | PROLIFERATION | - |
dc.title | CYR61 controls p53 and NF-kappa B expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000299462600010 | - |
dc.identifier.doi | 10.1016/j.canlet.2011.10.016 | - |
dc.identifier.bibliographicCitation | CANCER LETTERS, v.315, no.1, pp.86 - 95 | - |
dc.identifier.scopusid | 2-s2.0-81955167355 | - |
dc.citation.endPage | 95 | - |
dc.citation.startPage | 86 | - |
dc.citation.title | CANCER LETTERS | - |
dc.citation.volume | 315 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Kwang-Beom | - |
dc.contributor.affiliatedAuthor | Park, Chan-Yong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | CCN1 (CYR61) | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Carboplatin | - |
dc.subject.keywordAuthor | NF-kappa B | - |
dc.subject.keywordAuthor | PI3K/Akt | - |
dc.subject.keywordAuthor | Ovarian carcinoma cells | - |
dc.subject.keywordPlus | IMMEDIATE-EARLY GENE | - |
dc.subject.keywordPlus | CCN FAMILY | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | ENDOMETRIAL CANCER | - |
dc.subject.keywordPlus | TUMOR-SUPPRESSOR | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | BCL-2 | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.